



Cinvanti[®] (aprepitant) – Expanded indication

- On October 22, 2019, [Heron Therapeutics announced](#) the [FDA approval](#) of [Cinvanti \(aprepitant\)](#), in combination with other antiemetic agents in adult patients for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen.
 - Previously, Cinvanti was only approved as a 3-day regimen for adult patients in combination with other antiemetic agents for nausea and vomiting associated with initial and repeat courses of MEC.
 - Cinvanti is also approved in combination with other antiemetic agents in adult patients for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose [cisplatin](#) as a single-dose regimen.
 - Cinvanti has not been studied for the treatment of established nausea and vomiting.
- The Cinvanti label expansion standardizes the Cinvanti 130 mg single-dose regimen for patients receiving HEC and/or MEC as an injection over 2 minutes or an infusion over 30 minutes, further simplifying dosing and administration and eliminating the need to take oral aprepitant on days 2 and 3 following MEC administration.
- The most common adverse reactions ($\geq 2\%$) with single-dose Cinvanti were headache and fatigue.
- The recommended single-dose regimen of Cinvanti for HEC and MEC is 130 mg intravenously as an injection over 2 minutes or an infusion over 30 minutes on day 1 of chemotherapy.
 - Cinvanti should be given with [dexamethasone](#) and a 5-HT₃ antagonist. Refer to the Cinvanti drug label for dexamethasone dosing recommendations. Refer to the particular 5-HT₃ antagonist label for dosing recommendations.
 - Refer to the Cinvanti drug label for dosing recommendations for the 3-day MEC regimen.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.